ArticleEye (London, England)2025
Ophthalmological manifestations in a cohort of Cowden syndrome patients in a large tertiary healthcare system.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesCowden syndrome (CS) is a rare genetic disorder caused by mutations in the PTEN gene associated with multisystem hamartomas and predisposition to malignancies. Although ocular involvement has been reported in case studies, systematic data are lacking. This study aimed to evaluate the prevalence, characteristics, and genotypic associations of ocular manifestations in CS patients within a large tertiary healthcare system. SUBJECTS/
methodsWe conducted a retrospective cohort study using the Mass General Brigham (MGB) Research Patient Data Registry, encompassing over 6 million patients from 2005 to 2024. Patients meeting clinical or genetic criteria for CS were identified. Ophthalmic findings, genotype-phenotype correlations, and clinical follow-up were extracted and analysed. A comprehensive literature review on CS-related ocular findings was performed to contextualize findings.
resultsOf the 6,026,276 patients in the RPDR, 144 patients carried the diagnostic codes for CS. After a manual review of all charts, 77 met the clinical or genetic criteria for CS. Of these, 17 (22%) underwent ophthalmologic evaluation, and 4 (5%) exhibited CS-related ocular findings, including retinal hamartoma, eyelid hemangioma, trichilemmoma, and a peripapillary hamartoma-like lesion. Most patients maintained excellent vision over a median follow-up of four and a half years. Retinal imaging was limited, with OCT and OCTA available in only one case. Genotype analysis revealed that truncating PTEN variants were more likely associated with central nervous system involvement. Literature review identified a broader spectrum of ocular anomalies in CS, underscoring phenotypic variability.
conclusionsThe prevalence of CS in a large US tertiary setting is 1.28/100,000. Ocular manifestations in CS are rare and typically benign, with preserved vision in most cases. However, variability in presentation and mutation types may influence the risk. Notably, three of the four patients with ocular findings, possibly associated with CS, carried truncating variants. The fourth was PTEN-positive, but the specific variant was not retrievable. Multicentre studies are warranted to better define the full ocular phenotype of CS and to guide screening recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.